Prioritizing Muscle Health for Sustainable Weight Loss with GLP-1 Drugs

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide and tirzepatide have revolutionized the treatment of obesity and type 2 diabetes by promoting significant weight loss. However, a major concern with rapid weight reduction, particularly that achieved with these potent medications, is the undesirable concurrent loss of lean muscle mass. This review highlights the critical need to implement targeted strategies that preserve muscle mass during GLP-1 RA-induced weight loss to ensure long-term metabolic health and sustainable results.

The review consistently found that while GLP-1 RA-induced weight loss is substantial, often leading to a 15% to 20% reduction in initial body weight, a considerable and concerning proportion of this loss, typically 20% to 40%, can be attributed to lean muscle mass. This disproportionate muscle loss can lead to several adverse outcomes, including a reduced basal metabolic rate, impaired physical function, and an increased risk of sarcopenia (age-related muscle wasting). The most critical finding emphasized that combining GLP-1 RA therapy with structured resistance training and an adequate dietary protein intake (e.g., 1.0-1.6 grams per kilogram of body weight per day) can significantly mitigate muscle loss, potentially reducing it by up to 50% compared to weight loss achieved through diet alone. Studies suggest that patients who actively engage in such integrated programs can preserve an additional 2 to 3 kilograms of lean mass over 6 to 12 months of treatment, leading to better long-term weight maintenance and improved insulin sensitivity.